This Article  • Full text  • PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Contact me when this article is cited  Related Content  • Related article  • Similar articles in this journal

	Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings.

In reply

Dr Mikhail raised questions about our article on the treatment of patients with diabetes with extended-release nicotinic acid (niacin).¹ First, he correctly noted that there were mistakes in linking reference numbers in the text to those in the reference list. Unfortunately, in the final editing process, errors occurred that were not identified, so some references are misnumbered. Second, he emphasized that the study should not be generalized to include niacin therapy in all patients with diabetes. Certainly all patients with diabetes are not candidates for niacin therapy. As pointed out by the National Cholesterol Education Program,² the primary aim of lipid-lowering therapy in patients with diabetes is to achieve goals for low-density lipoprotein cholesterol level. Thereafter, consideration can be given to adding other lipid-lowering agents to achieve goals for non–high-density lipoprotein cholesterol levels and to favorably modify atherogenic dyslipidemia (high triglyceride and low high-density lipoprotein levels).

Niacin is . . . [Full Text of this Article]

RELATED ARTICLE

The Use of Niacin in Diabetes Mellitus
Nasser Mikhail
Arch Intern Med. 2003;163(3):369.
EXTRACT | FULL TEXT